Jinyu Bio-technology Co., Ltd. (SHA:600201)

Market Cap	7.60B
Revenue (ttm)	1.35B
Net Income (ttm)	164.86M
Shares Out	1.12B
EPS (ttm)	0.15
PE Ratio	45.66
Forward PE	36.39
Dividend	0.08 (1.18%)
Ex-Dividend Date	Jul 15, 2024

Volume	14,964,000
Average Volume	20,949,927
Open	6.94
Previous Close	6.93
Day's Range	6.78 - 6.96
52-Week Range	5.62 - 10.95
Beta	0.76
RSI	44.48
Earnings Date	Apr 25, 2025

About Jinyu Bio-technology

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary products in China. Its product portfolio includes Jinyu Baoling, Yangzhou Youbang, and Liaoning Yikang animal vaccines for the prevention of foot, porcine, mycoplasma pneumoniae, porcine reproductive and respiratory syndrome, porcine pseudorabies, pathogenic avian influenza, brucellosis bacterial disease, bovine viral diarrhea and mucosal, infectious rhinotracheitis, and other domestic animal diseases. The company was founded in 1992 and i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,654
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600201

Financial Performance

In 2023, Jinyu Bio-technology's revenue was 1.60 billion, an increase of 4.55% compared to the previous year's 1.53 billion. Earnings were 283.63 million, an increase of 34.64%.